Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Citius Pharmaceuticals Inc CTXR

Healthcare
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. It develops and commercializes critical care products with a focus on oncology, anti-infectives in adjunct cancer care, prescription products and stem cell therapy. Its products include LYMPHIR, Mino-Lok, Halo-Lido, NoveCite and Mino-Wrap. LYMPHIR is an engineered IL-2 diphtheria toxin fusion protein, for the treatment of... see more

Recent & Breaking News (NDAQ:CTXR)

Citius Pharmaceuticals to Present at the 7th Annual LD Micro Invitational

PR Newswire June 6, 2017

Citius Pharma Announces Addition of South America to World License

PR Newswire March 23, 2017

Citius Pharmaceuticals Inc. to Present at The MicroCap Conference on April 4th at 9:30 AM ET in New York City at the Essex House

Accesswire March 22, 2017

Survey Shows Catheter Salvage in CLABSI Patients Highly Desirable

PR Newswire March 1, 2017

Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

PR Newswire February 10, 2017

Citius' Mino-Lok™ Addresses Resistant Pathogens

PR Newswire January 11, 2017

Citius Pharmaceuticals to Present at 9th Annual Biotech Showcase

PR Newswire December 21, 2016

Drug Master File Submitted to FDA for Citius' Ethanol

PR Newswire December 19, 2016

Citius Moves Forward with Mino-Lok™ Phase 3 Trial

PR Newswire December 8, 2016

Citius Pharmaceuticals to Present at the 9th Annual LD Micro Main Event

Accesswire November 21, 2016

Citius Pharmaceuticals to Present at the Dawson James 2016 Small Cap Growth Stock Conference

PR Newswire October 20, 2016

Online Media Group covers Phase 3 clinical Trial

PR Newswire October 4, 2016

Citius Announces Completion of In-Depth Interviews on Patient-Reported Outcomes: Signs and Symptoms of Hemorrhoids and Treatments

Canada NewsWire August 23, 2016

Citius Announces Completion of In-Depth Interviews on Patient-Reported Outcomes: Signs and Symptoms of Hemorrhoids and Treatments

PR Newswire August 23, 2016

Citius Pharmaceuticals, Inc. Announces Appointment of Dr. Eugene Holuka to Its Board of Directors

PR Newswire June 28, 2016

Citius Announces Completion of Private Placement Financing

PR Newswire May 12, 2016

Citius Pharmaceuticals Completes Acquisition of Leonard-Meron Biosciences

PR Newswire April 4, 2016

Citius Pharmaceuticals Announces Significant Equity Investment from Chairman and CEO

PR Newswire March 23, 2016

Citius Pharmaceuticals Signs Letter of Intent to Acquire Leonard Meron Biosciences

PR Newswire March 7, 2016

Citius Pharmaceuticals Announces Results from Phase 2a Trial of Hydrocortisone and Lidocaine Combination Cream in Patients with Grade I and II Hemorrhoids

PR Newswire February 1, 2016